Gain Therapeutics Inc
General ticker "GANX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $45.3M
Gain Therapeutics Inc does not follow the US Stock Market performance with the rate: -23.8%.
Estimated limits based on current volatility of 4.4%: low 1.52$, high 1.66$
Factors to consider:
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [1.51$, 3.86$]
- 2024-12-30 to 2025-12-30 estimated range: [1.58$, 3.91$]
Financial Metrics affecting the GANX estimates:
- Negative: Non-GAAP EPS, $ of -1.71 <= 0.10
- Negative: Operating profit margin, % of -99.75 <= 1.03
- Negative: Operating cash flow per share per price, % of -37.15 <= 2.35
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
- Negative: negative Net income
Short-term GANX quotes
Long-term GANX plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.16MM | $0.14MM | $0.06MM |
| Operating Expenses | $13.99MM | $17.92MM | $22.31MM |
| Operating Income | $-13.83MM | $-17.78MM | $-22.25MM |
| Non-Operating Income | $-0.06MM | $0.28MM | $0.06MM |
| R&D Expense | $7.16MM | $8.38MM | $11.52MM |
| Income(Loss) | $-13.89MM | $-17.50MM | $-22.19MM |
| Taxes | $0.00MM | $0.09MM | $0.08MM |
| Profit(Loss) | $-13.89MM | $-17.59MM | $-22.27MM |
| Stockholders Equity | $34.82MM | $18.88MM | $12.58MM |
| Assets | $38.99MM | $24.10MM | $18.61MM |
| Operating Cash Flow | $-12.37MM | $-14.69MM | $-18.87MM |
| Capital expenditure | $0.09MM | $0.12MM | $0.02MM |
| Investing Cash Flow | $-0.09MM | $-14.77MM | $10.22MM |
| Financing Cash Flow | $41.77MM | $-0.08MM | $12.64MM |
| Earnings Per Share* | $-1.37 | $-1.48 | $-1.71 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.